Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
US10098909B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2017 |
| Grant date | Oct 16, 2018 |
| Priority date | — |
| Expiry date | Feb 6, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composition comprising a pharmaceutically effective amount of LISPRO.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.